<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546802</url>
  </required_header>
  <id_info>
    <org_study_id>288/18</org_study_id>
    <nct_id>NCT04546802</nct_id>
  </id_info>
  <brief_title>HepATocellular Cancer Hcv Therapy Study</brief_title>
  <acronym>HATCHeT</acronym>
  <official_title>Open Label Trial to Study the Efficacy and Safety of MK-5172 and MK-8742 +/- Ribavirin (RBV) in the Treatment of Hepatitis C G1 and 4, in Patients Eligible for Liver Transplant (HCC) or Curative Therapy or Clinically Stable Disease Post Local Resection, Embolization or Ablative Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austin Hospital, Melbourne Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with Hepatitis C Virus (HCV) infection, genotype 1 or 4 and with hepatocellular&#xD;
      carcinoma (HCC) and a complete response to HCC therapy will be randomised to immediate or&#xD;
      delayed (6 months) HCV therapy with Elbasvir (MK-8742) and Grazoprevir (MK-5172) [EBR/GZR].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two cohorts (A and B) of patients with chronic HCV infection will be enrolled. Patients will&#xD;
      be eligible for enrollment if they fulfill the study inclusion and exclusion criteria and&#xD;
      have achieved a complete tumour response (CR) 3 months (+/- 14 days) following HCC treatment&#xD;
&#xD;
        -  Cohort A: Patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A HCC who have&#xD;
           received curative therapy defined as either; liver transplantation, surgical resection&#xD;
           or local ablation with curative intent and attained a radiologically confirmed CR.&#xD;
           (N=50)&#xD;
&#xD;
        -  Cohort B: Patients who are non-eligible for curative therapy but have attained a&#xD;
           radiologically confirmed CR. post embolization or ablative therapy and have chronic HCV&#xD;
           infection. (N=50) Given the existing uncertainty regarding the impact of direct acting&#xD;
           antiviral (DAA) therapy on HCC recurrence, study participants will be randomized to&#xD;
           receive DAA treatment as &quot;immediate&quot; ie upon study enrollment or &quot;delayed&quot; ie treatment&#xD;
           commenced ≥ 6months following documentation of complete response based on radiological&#xD;
           assessment indicating no residual arterial enhancing disease..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Recruitment will be too difficult due to available PBS funded treatment and recent Australian&#xD;
    clinical guidelines will conflict with the premise of the study.&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral eradication</measure>
    <time_frame>12 weeks</time_frame>
    <description>Eradication of Hepatitis C virus determined by undetectable viral load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCC recurrence rate following HCC treatment</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>impact of DAA therapy on 6 and 12 month HCC recurrence rate following HCC treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Recurrence free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HCC recurrence / progression</measure>
    <time_frame>5 years</time_frame>
    <description>Time to HCC recurrence / progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Safety and tolerability of Elbasvir/grazoprevir determined by adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall survival determined by proportion surviving</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatoma</condition>
  <condition>Liver Cell Carcinoma</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Immediate treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo immediate treatment of the HCV once HCC complete response (CR) has been confirmed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will delay commencement of the HCV treatment until 6 months after HCC complete response (CR) has been confirmed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir / Grazoprevir Oral Tablet</intervention_name>
    <description>Elbasvir / Grazoprevir</description>
    <arm_group_label>Delayed treatment</arm_group_label>
    <arm_group_label>Immediate treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatitis C diagnosed as the HCV RNA (≥ 10,000 IU/mL in peripheral blood) at the time&#xD;
             of screening&#xD;
&#xD;
          -  Genotype inclusions&#xD;
&#xD;
          -  Have documented chronic HCV GT1 or GT4, (with no evidence of nontypeable or mixed&#xD;
             genotype) infection&#xD;
&#xD;
          -  HCC diagnosed on the basis of histology or according to AASLD radiological criteria,&#xD;
&#xD;
          -  Written informed consent granted prior to initiation of any study-specific screening&#xD;
             procedures&#xD;
&#xD;
          -  Patients aged 18 to 70 years-old;&#xD;
&#xD;
          -  Child-Pugh ≤≤ A6&#xD;
&#xD;
          -  BCLC stage 0, A HCC or no detectable HCC in a patient who has undergone a curative&#xD;
             form of treatment (liver transplantation, surgical resection of local ablative therapy&#xD;
             with curative intent) OR BCLC-B disease but clinically stable with non-evidence of&#xD;
             disease progression as demonstrated by either Triphasic CT or contrast MRI at least 3&#xD;
             months after the last HCC treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolment in other investigation / experimental therapies&#xD;
&#xD;
               -  Prior or current use of Sorafenib or other systemic chemotherapy&#xD;
&#xD;
               -  Life expectancy &lt; 12 months (unless transplantation eligible)&#xD;
&#xD;
               -  Unable to provide informed consent&#xD;
&#xD;
               -  Previous or concurrent cancer that is distinct from HCC in primary site or&#xD;
                  histology, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and&#xD;
                  superficial bladder tumors (Ta, Tis &amp; T1). Any cancer curatively treated &gt; 3&#xD;
                  years prior to enrollment is permitted.&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would impair participation in&#xD;
             the trial.&#xD;
&#xD;
          -  Coinfected with human immunodeficiency virus (HIV) infection or Hepatitis B virus&#xD;
             (e.g. HBsAg positive).&#xD;
&#xD;
          -  History of congestive heart failure defined as Class II to IV per New York Heart&#xD;
             Association (NYHA) classification within 6 months prior to study entry; active&#xD;
             coronary artery disease (CAD); clinically significant bradycardia or other&#xD;
             uncontrolled, cardiac arrhythmia defined as ≥ Grade 3 according to National Cancer&#xD;
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03,&#xD;
             or uncontrolled hypertension; myocardial infarction occurring within 6 months prior to&#xD;
             study entry (myocardial infarction occurring &gt; 6 months prior to study entry is&#xD;
             permitted)&#xD;
&#xD;
          -  Active clinically serious infections defined as ≥ Grade 3 according to NCI CTCAE,&#xD;
             version 4.03 6. Any medical, psychological, or social conditions, particularly if&#xD;
             unstable, including substance abuse, that may, in the opinion of the Investigator,&#xD;
             interfere with the subject's safety or participation in the study, protocol&#xD;
             compliance, or evaluation of the study results&#xD;
&#xD;
          -  Concomitant interferon therapy or therapies for active Hepatitis C Virus (HCV)&#xD;
             infection. Prior interferon and/or ribavirin therapy is not a contraindication to&#xD;
             enrolment however previous treatment with direct acting antiviral treatment is an&#xD;
             exclusion&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Inability to swallow oral medications&#xD;
&#xD;
          -  Clinically significant gastrointestinal bleeding occurring ≤ 3 months prior to study&#xD;
             entry or Large gastric-esophageal varices (larger than 5 cm) or previous history of&#xD;
             gastric-esophageal bleeding due to varices.&#xD;
&#xD;
          -  Fulfills exclusion criteria on biochemistry results:&#xD;
&#xD;
               -  Creatinine Clearance &lt;50 mL/min&#xD;
&#xD;
               -  Hemoglobin &lt;11 g/dL for females and &lt;12 g/dL for males&#xD;
&#xD;
               -  Platelets &lt;75 x 103/μL&#xD;
&#xD;
               -  Serum Albumin &lt; 3.0 g/dL&#xD;
&#xD;
               -  INR &gt;1.7&#xD;
&#xD;
               -  HbA1c &gt;10%&#xD;
&#xD;
               -  ALT &gt;10XULN, AST &gt;10XULNtherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William kemp, MBBSFRACPPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bayside Health</investigator_affiliation>
    <investigator_full_name>Ms. Rowan Frew</investigator_full_name>
    <investigator_title>Manager Research and Ethics Department</investigator_title>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>Elbasvir/grazoprevir</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Grazoprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

